Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck

Colorectal Neoplasms

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Digestive System Neoplasms, Gastrointestinal Neoplasms

Advanced Colorectal Cancer

Colorectal Neoplasms, Neoplasm, Residual

Colorectal Cancer Metastatic

Colorectal Neoplasms

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Oligodendroglioma

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Locally Recurrent Rectal Cancer

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck

Colorectal Cancer Metastatic

HPV-Negative Squamous Cell Carcinoma

Neoplasms, Colorectal Neoplasms

Rectal Neoplasms

Head and Neck Neoplasms

Carcinoma, Squamous Cell, Laryngeal Diseases

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Rectal Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Neoplasms

Colorectal Neoplasms

Colorectal Cancer Metastatic

Locally Advanced Hypopharyngeal Carcinoma

Colorectal Cancer Metastatic

Colorectal Neoplasms

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

Colorectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Clinical Trials

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

CEIL

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

NEORAF

ERBIOTAX

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

CRIT

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

AVEC-119

VICPROIRI

ECLYPse

BRAVE

CIFRA

TORCH-R

Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

EVIDENT